Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ovarian Cancers Clear all
Completed Phase 2 Interventional

Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma

NCT00157560
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Chemotherapy, multiple agents
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Jun 25, 2026, 4:23 AM EDT
Terminated Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

NCT01016054
View directory record Official record
Conditions
Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Interventions
AGS-8M4, Pegylated liposomal doxorubicin (PLD), gemcitabine, carboplatin
Biological · Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer
Interventions
Riluzole, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 4:23 AM EDT
Completed No phase listed Observational

Connecting Audio and Radio Sensing Systems to Improve Care at Home

NCT05344950
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Audio + Radio (AURA)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 25, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction

NCT00757952
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fourier transform ion cyclotron resonance mass spectrometry, chromatography, diagnostic laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Pine Street Foundation
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
4
States / cities
San Anselmo, California • San Francisco, California • Orono, Maine
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jun 25, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352
View directory record Official record
Conditions
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Interventions
DPX-Survivac, Cyclophosphamide, Pembrolizumab
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00006391
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
oxaliplatin, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Jun 25, 2026, 4:23 AM EDT
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003560
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Phase 1 Interventional

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07229313
View directory record Official record
Conditions
Advance Solid Tumors
Interventions
KIVU-107
Drug
Lead sponsor
Kivu Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

NCT03821233
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW49
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849
View directory record Official record
Conditions
Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
Interventions
kisspeptin 112-121
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 25, 2026, 4:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

NCT02896452
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Idiopathic Intracranial Hypertension
Interventions
Not listed
Lead sponsor
National Aeronautics and Space Administration
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

NCT00786838
View directory record Official record
Conditions
Solid Tumor
Interventions
Trabectedin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Charlotte, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

NCT01154452
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Phase 1 Interventional

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

NCT03968406
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Radiation Therapy, Talazoparib
Other · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer

NCT04473833
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Serial Transvaginal Ultrasonography
Procedure
Lead sponsor
John R van Nagell
Other
Eligibility
24 Years and older · Female only
Enrollment
65,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels

NCT00579540
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Flax Seed Oil, Fish Oil, Soybean Oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Access to Genetic Testing in Underserved Patients With Cancer

NCT06422455
View directory record Official record
Conditions
Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
Interventions
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study, Rucaparib Camsylate
Other · Biological · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jun 25, 2026, 4:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003064
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, etoposide phosphate, paclitaxel, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 25, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

NCT00410657
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Jun 25, 2026, 4:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 4:23 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592
View directory record Official record
Conditions
Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions
niraparib, Physician's choice
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jun 25, 2026, 4:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

NCT00930228
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Flutamide, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jun 25, 2026, 4:23 AM EDT